<DOC>
	<DOCNO>NCT01100307</DOCNO>
	<brief_summary>The purpose study assess efficacy pegaptanib sodium 0.3 mg compare sham injection confirm safety pegaptanib sodium 0.3 mg subject diabetic macular edema .</brief_summary>
	<brief_title>A Phase 3 Study To Compare The Efficacy And Safety Of 0.3 MG Pegaptanib Sodium To Sham Injections In Subjects With Diabetic Macular Edema</brief_title>
	<detailed_description>During study , issue report concern proper maintenance treatment masking ( See Result : Limitations Caveats )</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Retinal Diseases</mesh_term>
	<criteria>Type I , Type II diabetic subject Subjects must macular edema involve center field macula 3 . Foveal thickness least 250 Î¼m 4 . Best correct distance visual acuity study eye must letter score 68 35 inclusive Eyes prior panretinal photocoagulation ( PRP ) less 4 month prior baseline eye PRP need likely need within next 9 month HbA1C level &gt; 12 % recent sign uncontrolled diabetes Atrophy/scarring/fibrosis involve center macula , include evidence laser treat atrophy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>diabetic macular edema</keyword>
	<keyword>Macugen</keyword>
	<keyword>sham-controlled study</keyword>
</DOC>